half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-12. Anything still debated is marked as such rather than presented as settled.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
=== Macrocyclic chiral stationary phases === Macrocyclic chiral stationary phases consist of a silica support, on which macrocyclic antibiotic molecules are bonded. The commonly used macrocyclic antibiotics include rifamycin, glycopeptides (for example, avoparcin, teicoplanin, ristocetin A, vancomycin, and their analogs), polypeptide antibiotic thiostrepton, and aminoglycosides (for example, fradiomycin, kanamycin, and streptomycin). The macrocyclic antibiotics interact with the analyte through hydrogen bonds, dipole-dipole interactions with the polar groups of the analyte, ionic interactions and π-π interactions.
Photoacoustic Tomography (PAT) is a hybrid imaging modality that utilizes the photoacoustic effect without the use of ionizing radiation. It works without contact with very fast laser pulses that generate ultrasound in the tissue under examination. The local absorption of the light leads to sudden local heating and the resulting thermal expansion. The result is broadband acoustic waves. The original distribution of absorbed energy can be reconstructed by measuring the outgoing ultrasound waves with appropriate ultrasound transducers.
Although both acids cause a Pd+ orange to orange-red medulla reaction, a potassium (K) spot test can separate the species: the medulla of P. perlatum turns yellow (K+ yellow), whereas in P. stuppeum, the yellow colour turns red (K+ yellow turning red). Parmotrema perlatum can be distinguished from other sorediate and marginally ciliate species like P. arnoldii and P. robustum by the presence of the stictic acid chemosyndrome. Also, the medulla of P. arnoldii fluoresces strongly when lit with an ultraviolet lamp. Parmotrema perlatum is similar to P. crinitum due to both species having a brown to tan, erhizinate marginal zone and the presence of the stictic acid chemosyndrome in the medulla. However, P. crinitum can be distinguished by its isidiate upper surface. Another potential lookalike, P. margaritatum, is distinguished from P. perlatum by the K+ (red) reaction of its medulla. Cetrelia cetrarioides has been documented as a lookalike, presumably because of the cilia on its thallus margin, and the presence of atranorin and the stictic acid chemosyndrome.
Corporate real estate Class A office space Commercial Information Exchange Estoppel certificate, a document used in International real estate Owner Occupied Commercial Real Estate Real estate Real estate investing Real estate economics
The requirement of arginine in the urea cycle is reduced, as dogs have a functional pyrroline-5-carboxylate synthase. Dogs have a functional delta 6 desaturase, hence no specific need for arachidonic acid. Dogs have a functional sulfinoalanine decarboxylase and can synthesise taurine from methionine and cysteine; however, some breeds have a genetic predisposition to taurine deficiency. Taurine supplementation is recommended for dogs at risk of taurine deficiency and dogs with dilated cardiomyopathy. Unlike cats, dogs and humans can use Vitamin D2 nearly as efficiently as they use Vitamin D3.
Sources: en.wikipedia.org
== Provitamin A activity == Plant carotenoids are the primary dietary source of provitamin A worldwide, with β-carotene as the best-known provitamin A carotenoid. Others include α-carotene and β-cryptoxanthin. Carotenoid absorption is restricted to the duodenum of the small intestine. One molecule of β-carotene can be cleaved by the intestinal enzyme β,β-carotene 15,15'-monooxygenase into two molecules of vitamin A.
== Production and development == Mulligan Stew was developed in early 1971 by the USDA Extension Service, and filmed by the USDA Motion Picture Service (which for many years prior produced educational cinematic films and TV programs for public viewing). Mulligan Stew was developed based on plan and design proposals by Developmental Committees, Iowa State University Extension Service 4-H Nutrition Television Programs. The Expanded Food and Nutrition Education Program (EFNEP) provided a grant to produce the series. (4-H is the official youth outreach and development program of the land-grant universities' Cooperative Extension Services and USDA.) The target audience of the program was older elementary school students, fourth through sixth grade. Eleanor Wilson, the national 4-H TV coordinator at the time, was tapped to be the series' technical advisor. Wilson subcontracted with Iowa State University to develop an outline of educational concepts for the series. USDA Extension then hired Ira Klugerman to direct the series. Klugerman, who came from a background of children's television at WQED in Pittsburgh, Pennsylvania, came up with the title and general treatment for the series. V. "Buddy" Renfro was the credited producer. Production began on location in southeast Washington, DC in 1971 (the opening sequence was filmed at RFK Stadium). Other filming locations included major production partner Michigan State University's home base of Lansing, Michigan, and on location for one episode at Johnson Space Center in Houston.
On June 3, 1942, which was during World War II, in what were the only two invasions of the United States during the war, small parts of the Aleutian islands were occupied by Japanese forces, when Attu and Kiska were invaded possibly to divert American forces away from the main Japanese attack at Midway Atoll. The U.S. Navy, having broken the Japanese naval codes, proceeded as if this was just a diversion, and it did not expend large amounts of effort in defending the islands. More than 90 Americans were taken to Japan as prisoners of war. The United States moved most of the remaining civilian population (over 800) of the Aleutians and Pribilovians to camps in the Alaska Panhandle. In May 1943, American forces invaded Japanese-held Attu and defeated the Japanese. In August 1943, American and Canadian troops launched an invasion of Kiska, in which 34,426 men composed of both Americans and Canadian participated; however, Japanese forces had already evacuated the island, ending the campaign in the islands. The invasion was an embarrassment for the Allied forces as the entire Japanese force of 5,183 men had left the island on July 28 without the Americans noticing; however, the Americans suffered significant casualties during their "invasion"—313 men died as a result of accidents, with many dying due to accidental fire. President Roosevelt visited Adak in 1944, meeting with commanders and eating with soldiers of the garrison. This was his first and only trip to the Aleutian Islands and Alaska as a whole.
== Tissue distribution and secretion == Human and mouse PGLYRP2 is constitutively expressed in the adult and fetal liver, from where it is secreted into the blood. PGLYRP2 (NAMLAA) is present in human plasma at 100 to 200 μg/mL and at lower concentrations in saliva, milk, cerebrospinal fluid, and synovial fluid. PGLYRP2 is also expressed to a much lower level in the colon, lymph nodes, spleen, thymus, heart, and polymorphonuclear leukocyte granules. PGLYRP2 is differentially expressed in the developing brain and this expression is influenced by the intestinal microbiome. Bacteria and cytokines induce low level of PGLYRP2 expression in the skin and gastrointestinal and oral epithelial cells, and also in intestinal intraepithelial T lymphocytes, dendritic cells, NK (natural killer) cells, and inflammatory macrophages. Some mammals, e.g. pigs, express multiple splice forms of PGLYRP2 with differential expression. Bacteria and cytokines induce expression of PGLYRP2 in epithelial cells through the p38 mitogen activated protein kinase (MAPK) and IRAK1 (interleukin-1 receptor-associated kinase 1) signaling pathways. Constitutive and induced expression of PGLYRP2 is controlled by different transcription factors whose binding sequences are located in different regions of the PGLYRP2 promoter. Constitutive expression of PGLYRP2 in hepatocytes is regulated by transcription factors c-Jun and ATF2 (activating transcription factor 2) through sequences in the proximal region of the promoter.
Sources: en.wikipedia.org
== Clinical significance relevance == The protein UBC9 encoded by the UBE2I gene has been shown to be targeted by multiple viruses, including HIV and HPV. It has been hypothesized that these viruses hijack UBC9 to serve their own purposes.
=== 1970s === Following Giant-Size X-Men, the X-Men comic was revived with issue #94 (August 1975), drawn by Cockrum and written by Chris Claremont. Wolverine is initially overshadowed by the other characters, although he creates tension in the team as he is attracted to Cyclops' girlfriend, Jean Grey. As the series progressed, Claremont considered dropping Wolverine from the comic; Cockrum's successor, artist John Byrne, championed the character, later explaining that as a Canadian himself he did not want to see the only Canadian character dropped. Byrne modeled his rendition of Wolverine on actor Paul D'Amato, who played Dr. Hook in the sports film Slap Shot (1977). Cockrum introduced another costume for Wolverine in the final issue of his run, but it was dropped at the start of Byrne's run because he found it difficult to draw. Wolverine was first drawn without his mask in X-Men #98 (April 1976); his distinctive hairstyle became one of his trademarks. The same issue also established that Wolverine's claws are an integrated part of his anatomy. X-Men #100 introduces the "fastball special", a combat maneuver in which the super-strong Colossus throws Wolverine at a distance as if he were a projectile weapon; this tactic recurs in many future battles. Stories of the late 1970s establish Wolverine's murky past and unstable nature, which he battles to keep in check. Wolverine's name was revealed as "Logan" in X-Men #103 (February 1977); Claremont drew inspiration from Canada's Mount Logan, liking "the idea [of] the tallest mountain being the name of the shortest character".
In Japan, Mochida Healthcare, a subsidiary of Mochida Pharmaceutical, produces a line of body soaps and shampoo under the brand name Collage (コラージュ) that contain miconazole nitrate as their main ingredient.
The white pulp of the cupuaçu has an odour described as a mix of chocolate and pineapple and is frequently used in desserts, juices and sweets. The juice tastes primarily like pear, banana, passion fruit, and melon. Chocolate made from cupuaçu, very similar to that made from cocoa, is called cupulate.
==== Jersey ==== The government of Jersey signed a confidential agreement with 3M in 2005, agreeing to not pursue legal claims for £2.6m. Jersey must assist 3M in the defense of future claims. A source told The Guardian that Jersey needed 3M's permission to proceed with blood tests to avoid 3M punitive measures. "The state got an agreement to do individual blood tests, but not screening, as that could be the first step towards a possible class action lawsuit."
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.